- Home
- CZNC vs ATYR Comparison
CZNC vs ATYR Comparison
Compare CZNC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- ATYR
- Stock Information
- Founded
- CZNC 1864
- ATYR 2005
- Country
- CZNC United States
- ATYR United States
- Employees
- CZNC N/A
- ATYR N/A
- Industry
- CZNC Major Banks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CZNC Finance
- ATYR Health Care
- Exchange
- CZNC Nasdaq
- ATYR Nasdaq
- Market Cap
- CZNC 330.3M
- ATYR 330.7M
- IPO Year
- CZNC N/A
- ATYR 2015
- Fundamental
- Price
- CZNC $20.24
- ATYR $3.91
- Analyst Decision
- CZNC
- ATYR Strong Buy
- Analyst Count
- CZNC 0
- ATYR 6
- Target Price
- CZNC N/A
- ATYR $18.60
- AVG Volume (30 Days)
- CZNC 23.5K
- ATYR 2.0M
- Earning Date
- CZNC 05-06-2025
- ATYR 03-13-2025
- Dividend Yield
- CZNC 5.56%
- ATYR N/A
- EPS Growth
- CZNC 7.45
- ATYR N/A
- EPS
- CZNC 1.69
- ATYR N/A
- Revenue
- CZNC $106,129,000.00
- ATYR $235,000.00
- Revenue This Year
- CZNC $9.38
- ATYR $1,387.23
- Revenue Next Year
- CZNC $3.77
- ATYR $873.22
- P/E Ratio
- CZNC $11.97
- ATYR N/A
- Revenue Growth
- CZNC 1.43
- ATYR N/A
- 52 Week Low
- CZNC $16.50
- ATYR $1.42
- 52 Week High
- CZNC $22.68
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- CZNC 46.12
- ATYR 57.44
- Support Level
- CZNC $19.58
- ATYR $2.98
- Resistance Level
- CZNC $20.51
- ATYR $3.73
- Average True Range (ATR)
- CZNC 0.51
- ATYR 0.40
- MACD
- CZNC -0.11
- ATYR 0.06
- Stochastic Oscillator
- CZNC 35.20
- ATYR 81.06
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.